Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Ocular Therapeutix, Inc.

35 indications, side-by-side phase, drug & LoA

$8.74

+0.13 (+1.53%)

C 58Pipeline Score Fair Value Pharma · Commercial
Market Cap
1.80 B
EPS
-1.46
P/E Ratio
-
Value Trade
16.90 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    10.79 M

  • R&D Expenses

    66.21 M

  • Operating CF

    -65.99 M

  • Total Assets

    732.53 M

  • Total Liabilities

    150.96 M

  • Equity

    581.57 M

  • D/E Ratio

    12,345

-11.41 %
Week
-13.73 %
1 Month
17.74 %
3 Month
-29.48 %
6 Month
-42.57 %
5 Year
-36.69 %
All Time
Cash Data
Healthy

  • Cash Position

    666.70 M

  • Monthly Burn

    22.00 M

  • Runway

    29.1 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 5, 2026
Overview
Volume
2.67 M
52 Week Range
6.23 - 16.44
% held by Insiders
8.76 %
% held by Institutions
89.17 %
Enterprise Value
1.21 B
Total Shares
217.61 M
Short %
14.01 %
Float Shares
179.10 M
Company Description
HQ: 14 CROSBY DRIVE, 3RD FLOOR, BE...
Employees:325
https://www.ocutx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout example
AXPAXLI (OTX-TKI) Wet age-related macular degeneration (wet AMD)
Phase 3
—
Small Molecules
Ophthalmologic System
AXPAXLI (OTX-TKI) Wet age-related macular degeneration (wet AMD)
Phase 3
—
Small Molecules
Ophthalmologic System
AXPAXLI (OTX-TKI) Wet age-related macular degeneration (wet AMD)
Phase 3
—
Small Molecules
Ophthalmologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C58
Pipeline Score
$2.0B
Pipeline Value
Fair Value
Valuation Signal
11
Drugs Scored
1.1x
rNPV / MCap
Top 84%
Micro Cap
(rank 146 of 905)
Percentile Rank
Ocular Therapeutix, Inc. carries a moderate pipeline score (58/100), with $5.1B risk-adjusted pipeline value, led by OTX-TKI in Neovascular Age-related Macular Degeneration (Phase 3), across $80B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
OTX-TKI
Small molecule		Neovascular Age-related Macular DegenerationPhase 3NCT0649591849% $1.7B ACTIVE NOT_RECRUITING 1,198 VERY_FAST B (69) Jan 8, 2027LOW_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
OCUL Clinical Trial Results & History
Drug Name Indications Phase Date Trial Results Summary Title Source
AXPAXLI
wet AMD
Phase 3
2025-08-06
AXPAXLI
wet AMD
Phase 3
2025-08-06
AXPAXLI
wet AMD
Phase 3
2025-08-06
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in OCUL
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Ocular Therapeutix, Inc. (OCUL) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
OCUL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OCUL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OCUL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
OCUL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
OCUL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
OCUL Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-260 0.00 0 0 - - - - - -
2026-06-260 0.00 0 0 - - - - - -
2026-06-260 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Real-Time OCUL Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
OCUL Option Volume & Put-Call Ratio
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Ocular Therapeutix, Inc. (OCUL) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How OCUL ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Diabetic Retinopathy #1 of 5 PHASE 3 Single intravitreal of axitinib hydrogel followed by a mock procedure at Week 24 + Intravitreal of axitinib hydrogel followed by a second intravitreal of the axitinib at Week 24
ABBV FDMT RYTM
$10.29B 0.99 LEADER
Age-Related Macular Degeneration #2 of 13 PHASE 3 OTX-TKI + Aflibercept
ABBV FDMT REGN
$15.43B 0.98 CONTENDER